Interest comes back, CRO names remain key focus for overseas investors We met c.40 investors in the Middle East / Europe / US during the past two weeks to provide China healthcare market updates and discuss topics including China drug out- licensing, CRO updates and outlooks. We shared with them our sector pecking order as Pharma, Contract Research Organizations (CRO), Biotech, Medical Devices, Pharmacy, Distribution, and Services, and our top stock ideas as Hengrui (600276 CH / 1276 HK, Buy), BeOne (6160 H ...